TP53 and melanoma: Furthermore, a single dose of pifithrin-α, a p53 inhibitor, sensitized melanoma cells in vivo and in vitro to BRAFi/MEKi, while the BRAFi/MEKi therapy increased the number of p53-expressing cells in melanoma tissue [28].